3 completed, 1 recruiting, 1 unknown. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Combination drug: new trials by email Literature Review of Combination drug trials Research Report on Combination drug
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies DS3790a, Combination drug - Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 420 | 2026-01-16 | 2026-08-24 |
| Niraparib and Dostarlimab in HRD Solid Tumors Combination drug - Homologous Recombination Deficient Solid Tumors | Phase 2 | Unknown | West Cancer Center | 30 | 2021-11-29 | 2023-12-21 |
| Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety Rogaratinib (BAY1163877), Combination drug - Cancer | Phase 2 | Completed | Bayer | 1 | 2019-10-30 | 2022-04-01 |
| Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization Combination drug - Ischemia, Anticoagulants | Phase 1 / Phase 2 | Completed | Mansoura University | 1536 | 2019-07-03 | 2022-07-19 |
| Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer Combination drug, Chemotherapy - Pancreatic Cancer | Phase 2 | Completed | Zhejiang University | 110 | 2019-03-27 | 2023-01-27 |
Acrocephalosyndactylia (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1) · Ischemia (1) · Lymphoma, B-Cell (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Bayer (1) · Daiichi Sankyo (1) · Mansoura University (1) · West Cancer Center (1) · Zhejiang University (1)
United States (2) · China (1) · Egypt (1) · France (1) · Italy (1) · Japan (1) · Switzerland (1)
Gregory Vidal, MD (1) · Nshaat A Elsaadany, MSc (1)
2019 (1), 2025 (1)